Source 1primary paper2026MED
Toolkit/CardioProtect
CardioProtect
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We selected a clone, designated CardioProtect, whose sensitivity was optimized to detect human AMI-relevant cTnI levels.
Usefulness & Problems
Why this is useful
CardioProtect is a selected engineered cell clone that detects cTnI and secretes tenecteplase. It is presented as the lead closed-loop therapeutic cell product in the study.; cTnI-triggered thrombolytic protein secretion; closed-loop detection and treatment proof-of-concept for AMI
Source:
CardioProtect is a selected engineered cell clone that detects cTnI and secretes tenecteplase. It is presented as the lead closed-loop therapeutic cell product in the study.
Source:
cTnI-triggered thrombolytic protein secretion
Source:
closed-loop detection and treatment proof-of-concept for AMI
Problem solved
It aims to provide early detection-linked treatment of AMI by releasing a thrombolytic agent only when the biomarker signal is present.; couples biomarker detection to inducible thrombolytic release with an external off-switch
Source:
It aims to provide early detection-linked treatment of AMI by releasing a thrombolytic agent only when the biomarker signal is present.
Source:
couples biomarker detection to inducible thrombolytic release with an external off-switch
Problem links
couples biomarker detection to inducible thrombolytic release with an external off-switch
LiteratureIt aims to provide early detection-linked treatment of AMI by releasing a thrombolytic agent only when the biomarker signal is present.
Source:
It aims to provide early detection-linked treatment of AMI by releasing a thrombolytic agent only when the biomarker signal is present.
Published Workflows
Objective: Engineer a closed-loop mammalian cell therapy system that detects cardiac troponin I as an early AMI biomarker and responds by releasing a thrombolytic agent.
Why it works: The workflow couples biomarker sensing through an engineered receptor to synthetic promoter control and therapeutic protein secretion, then validates the resulting closed-loop behavior in an ex vivo clot-lysis assay.
scFv-based extracellular cTnI recognitionrewired intracellular receptor signalingsynthetic promoter-driven gene expressioncTnI-induced tenecteplase secretiondoxycycline-triggered off-switchingmammalian cell engineeringmonoclonal clone construction and selectionex vivo blood culture validationalginate microencapsulation
Stages
- 1.TropR receptor engineering(library_design)
This stage creates the sensing architecture needed to convert cTnI detection into intracellular signaling and gene-expression control.
Selection: Design cTnI-sensing chimeric receptors using extracellular scFvs and alternative intracellular signaling domains.
- 2.Functional confirmation of cTnI-dependent signaling(functional_characterization)
This stage verifies that the receptor works in relevant mammalian cell contexts before building therapeutic output lines.
Selection: Confirm cTnI-dependent TropR functionality and synthetic-promoter control in HEK-derived cell lines and iPSC-derived cardiomyocytes.
- 3.Construction of therapeutic monoclonal cell lines(library_build)
This stage converts the sensing module into a therapeutic closed-loop cell product.
Selection: Build monoclonal cell lines for cTnI-induced tenecteplase secretion with a doxycycline-triggered off-switch.
- 4.Lead clone selection(hit_picking)
This stage narrows multiple monoclonal lines to a lead clone with sensitivity matched to human AMI-relevant biomarker levels.
Selection: Select a clone optimized to detect human AMI-relevant cTnI levels.
- 5.Ex vivo thrombolytic validation(confirmatory_validation)
This stage confirms that the selected therapeutic clone performs the intended closed-loop function in a clot-lysis assay.
Selection: Test whether alginate-microencapsulated CardioProtect cells lyse fibrin clots in an ex vivo blood culture system under cTnI induction and doxycycline repression.
Steps
- 1.Design cTnI-sensing TropR variantsengineered receptor
Create a chimeric receptor that senses cTnI and couples detection to intracellular signaling.
A sensing module is required before downstream gene-expression control and therapeutic output can be engineered.
- 2.Confirm cTnI-dependent TropR function in mammalian cellssensing construct under test
Verify that TropR drives synthetic-signaling-specific promoter outputs in response to cTnI.
Functional confirmation is needed before investing in therapeutic clone construction.
- 3.Construct monoclonal cTnI-inducible TNK-secreting cell lines with doxycycline off-switchtherapeutic cell construct
Build therapeutic cell lines that convert cTnI sensing into tenecteplase secretion while retaining external shutoff control.
Therapeutic output is added after receptor function is established.
- 4.Select CardioProtect as the lead cloneselected lead clone
Choose the monoclonal line with sensitivity optimized for human AMI-relevant cTnI levels.
A single optimized lead clone is needed before confirmatory thrombolysis validation.
- 5.Validate alginate-microencapsulated CardioProtect in ex vivo clot lysis assayencapsulated therapeutic cell product
Test whether the selected clone performs strict cTnI-inducible, doxycycline-repressible thrombolysis.
Confirmatory efficacy testing follows lead-clone selection to show the full closed-loop therapeutic behavior.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
biomarker-induced receptor signalinginducible gene expression controlreversible small-molecule repressionTechniques
Computational DesignTarget processes
recombinationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
Its implementation requires the cTnI-responsive sensing system, tenecteplase expression/secretion, and a doxycycline-triggered off-switch. The reported thrombolysis validation used alginate microencapsulation and an ex vivo blood culture system.; requires engineered monoclonal cell lines; requires tenecteplase secretion circuitry and doxycycline-responsive off-switching; ex vivo thrombolysis was shown with alginate-microencapsulated cells
The abstract only shows proof-of-concept and ex vivo clot lysis, so it does not establish clinical efficacy or in vivo therapeutic performance.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successCell-freeapplication demo
ex vivo blood culture clot-lysis assay
Inferred from claim c5 during normalization. Alginate-microencapsulated CardioProtect cells triggered complete fibrin-clot lysis in an ex vivo blood culture system in a strict cTnI-inducible and doxycycline-repressible manner. Derived from claim c5.
Source:
Supporting Sources
Ranked Claims
Alginate-microencapsulated CardioProtect cells triggered complete fibrin-clot lysis in an ex vivo blood culture system in a strict cTnI-inducible and doxycycline-repressible manner.
CardioProtect is a selected monoclonal engineered cell clone optimized to detect human AMI-relevant cTnI levels and to secrete tenecteplase under cTnI control with a doxycycline-triggered off-switch.
The study engineered a cell-based system to sense cardiac troponin I and respond by releasing a thrombolytic agent.
cTnI-dependent TropR function enabled rapid, reversible, tunable control of gene expression via synthetic-signaling-specific promoters in HEK-derived cell lines and iPSC-derived cardiomyocytes.
TropR is a chimeric receptor with extracellular scFvs that detects cTnI and signals through selected intracellular receptor domains associated with cardioprotective signaling.
The closed-loop strategy is presented as a proof-of-concept for using cell therapy in the early detection and treatment of acute myocardial infarction.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug cardioprotect
We selected a clone, designated CardioProtect, whose sensitivity was optimized to detect human AMI-relevant cTnI levels.
Source:
application demosupports
Alginate-microencapsulated CardioProtect cells triggered complete fibrin-clot lysis in an ex vivo blood culture system in a strict cTnI-inducible and doxycycline-repressible manner.
Source:
engineered system featuresupports
CardioProtect is a selected monoclonal engineered cell clone optimized to detect human AMI-relevant cTnI levels and to secrete tenecteplase under cTnI control with a doxycycline-triggered off-switch.
Source:
engineering objectivesupports
The study engineered a cell-based system to sense cardiac troponin I and respond by releasing a thrombolytic agent.
Source:
proof of conceptsupports
The closed-loop strategy is presented as a proof-of-concept for using cell therapy in the early detection and treatment of acute myocardial infarction.
Source:
Comparisons
Source-stated alternatives
The abstract notes that multiple monoclonal cell lines were constructed before selecting CardioProtect as the optimized clone.
Source:
The abstract notes that multiple monoclonal cell lines were constructed before selecting CardioProtect as the optimized clone.
Source-backed strengths
optimized to detect human AMI-relevant cTnI levels; supports strict cTnI-inducible and doxycycline-repressible clot lysis when microencapsulated
Source:
optimized to detect human AMI-relevant cTnI levels
Source:
supports strict cTnI-inducible and doxycycline-repressible clot lysis when microencapsulated
CardioProtect and cell-specific receptor subtype gene deletion mouse models address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice.
CardioProtect and CheRiff + jRCaMP1b + RH237 cardiac all-optical electrophysiology platform address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice.
Compared with eNpHR
CardioProtect and eNpHR address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice; may avoid an exogenous cofactor requirement.
Ranked Citations
- 1.